Moderna, Inc. (MRNA) Stock Price & Analysis

Moderna, Inc. (MRNA) rose 0.27% to USD 47.73 as of June 9, 2026 at 22:36 UTC, according to Nexqual real-time market data.

MRNA last closed at USD 47.6; the session ranged USD 45.4–48.42 on volume of 5,077,290 shares. Market capitalization is $18.94B, with a 52-week range of USD 22.28–59.55 (NMS). Source: Nexqual, June 9, 2026 at 22:36 UTC.

Key Statistics (as of June 9, 2026 at 22:36 UTC)

Technical Analysis (MRNA)

Nexqual's technical model rates MRNA "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 9, 2026 at 22:36 UTC.

Analyst Ratings (MRNA)

Wall Street analysts rate MRNA "Hold" based on 20 analysts, with a mean price target of USD 43.2 (range USD 21–69), per Nexqual as of June 9, 2026 at 22:36 UTC.

Earnings (MRNA)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financials & Fundamentals (MRNA)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Financial Health Score (MRNA)

Nexqual rates Moderna, Inc.'s overall financial health "Weak" across five dimensions, as of June 9, 2026 at 22:36 UTC.

Ownership (MRNA)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

Leadership (MRNA)

Moderna, Inc. is led by Stéphane Bancel (age 52), CEO & Director, per Nexqual as of June 9, 2026 at 22:36 UTC.

Major Backers & Investors (MRNA)

Notable institutional backers of Moderna, Inc. include FMR, LLC, Baillie Gifford, Capital Group, according to Nexqual as of June 9, 2026 at 22:36 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 22:36 UTC.

From Moderna, Inc.'s Latest SEC 10-K Filing (filed 2026-02-20)

Key Strengths & Strategy (as disclosed to the SEC)

• Any mRNA and LNP components that do not escape the endosome are typically delivered to lysosomes where they are degraded by the natural process of cellular digestion. 9 Table of Contents Examples of tools we developed by using our platform include proprietary LNP formulations that address the steps of mRNA delivery, including cell uptake, endosomal escape, and subsequent lipid metabolism, and for avoidance of counterproductive interactions with the immune system.
• We pursue updated vaccine compositions based on guidance from the FDA, and other regulatory bodies including European Medicines Agency (EMA) and the World Health Organization (WHO), with the goal of broadening vaccine-induced immunity and providing protection against circulating SARS-CoV-2 variants.
• We have developed an RSV vaccine (mRNA-1345 or mRESVIA) for adults. mRESVIA encodes an engineered form of the RSV F protein stabilized in the prefusion conformation and is formulated in our proprietary LNP.
• We filed for FDA approval for mRNA-1083 in November 2024 and also submitted regulatory applications in other geographies, including the EU, Canada, Australia and the UK.

Partnerships

• In September 2022, Merck exercised its option for personalized cancer vaccines (PCVs), including mRNA-4157, pursuant to the terms of our existing PCV Collaboration and License Agreement with Merck, which was amended and restated in 2018 (PCV Agreement, also referred to as the INT Agreement).
• In January 2026, we entered into a strategic collaboration with Recordati, an international pharmaceutical group, to advance mRNA-3927 through the final stages of clinical development and, if approved, global commercialization.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:36 UTC. This page is informational and not investment advice.